Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Rech J, Schett G.
Figueiredo CP, et al. Among authors: bang h.
Ann Rheum Dis. 2017 Feb;76(2):399-407. doi: 10.1136/annrheumdis-2016-209297. Epub 2016 Jun 20.
Ann Rheum Dis. 2017.
PMID: 27323772